HOME >> BIOLOGY >> NEWS
Chromium picolinate shows greater benefits in diabetes care than other forms of chromium

PURCHASE, NY, January 31, 2007 -- Nutrition 21, Inc. (NASDAQ: NXXI) reported today that a peer reviewed analysis on chromium picolinate was published in the current edition of Diabetes Technology & Therapeutics. The analysis confirms that chromium picolinate is effective in improving glycemic control and normalizing lipid levels in people with type 2 diabetes.(1) The review, which analyzed research on chromium picolinate, supports the consistent beneficial effects of chromium picolinate and refutes a previous review that analyzed efficacy after combining results from all types of supplemental chromium.(2)

"The main messages are that all forms of chromium are not equivalent, and that higher doses of chromium picolinate are required for people with type 2 diabetes," said C. Leigh Broadhurst, PhD, Research Chemist, the lead author of the publication. "Previous chromium reviews examined all types of chromium at widely varying doses. But separating out chromium picolinate, which yields highly consistent results in research studies, compared to other chromium supplements shows that at doses between 200--1000 mcg it is a superior nutritional adjunct to diabetes treatments."

The review analyzed 15 clinical studies of people with diabetes. All studies showed chromium picolinate produced benefits in one or more standard measures of diabetes management, with no adverse events reported. The studies examined people with type 2, type 1, gestational and corticosteroid-induced diabetes. Although glycemic control varied by trial, all 15 trials showed improvements in one or more measurements of glycemic control, including fasting glucose, postprandial glucose, fasting insulin, postprandial insulin, glycated hemoglobin, or insulin sensitivity. The authors concluded the greater bioavailability of chromium picolinate compared to other forms of chromium may explain its comparatively significant superior effects on glycemic and lipidemic control.

Su
'"/>


31-Jan-2007


Page: 1 2 3

Related biology news :

1. Clones on task serve greater good, evolutionary study shows
2. Research shows skeleton to be endocrine organ
3. An early ape shows its hand
4. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer
5. Huntingtons disease study shows animal models on target
6. Research shows NPD1 protects a key component of vision
7. Radiation therapy combined with microsurgery shows promise for curing injured spinal cord
8. Chitin from lobster shell shows great healing and bio-stimulant properties
9. Study shows cane sugar, corn sweeteners have similar effects on appetite
10. New research shows vaginal bacteria vary among healthy women, need customized treatment
11. Global warming is evaporating Arctic ponds, new study shows

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/21/2020)... ... May 21, 2020 , ... Agility ... Shore and Greater Boston area, is pleased to announce a partnership with Dallas-based ... busiest group practices in the area, Agility Orthopedics is focused on speeding up ...
(Date:5/11/2020)... ... May 11, 2020 , ... Octagos Health, a Houston-based ... implanted cardiac devices. The Octagos software allows healthcare professionals access to cardiac patients’ ... the management of remote transmissions and at the same time provides real-time patient ...
(Date:5/1/2020)... ... 30, 2020 , ... InBios International Inc., a leading developer ... awarded a contract from the Biomedical Advanced Research and Development Authority (BARDA), part ... U.S. Department of Health and Human Services, to develop the SCoV-2 Detect IgM/IgG ...
Breaking Biology News(10 mins):
(Date:5/14/2020)... (PRWEB) , ... May 12, 2020 , ... ... tools for translational research, is bringing together thousands of industry leaders, clinicians, research ... program highlights two plenary speakers, Carl June, MD, Director of the Center for ...
(Date:5/9/2020)... ... 08, 2020 , ... Worldwide Business with kathy ireland® will be ... May 10, 2020 and Wednesday, May 13, 2020 at 8:00pm ET / PT – ... key executives from Techolution and Bravado Pharmaceuticals . , As ...
(Date:5/5/2020)... , ... May 05, 2020 , ... ... company, announced today the launch of its iGlucose® LTE Cat-M Cellular ... solution utilizes LTE Cat-M1 technology, the industry’s newest and broadest cellular connectivity available, ...
(Date:4/23/2020)... ... 22, 2020 , ... Across the country, there is an ... Virginia has only been receiving 50% to 7.7% of the personal protective equipment ... Northam told the Virginia Mercury, “While we appreciate what we’ve received from the ...
Breaking Biology Technology:
Cached News: